Atai Life Sciences Nv (ATAI)
$1.3
+0.07
(+5.69%)▲
Performance
- $1.23$1.33$1.30
5.38%
Downside
Day's Volatility :7.52%
Upside
2.26%
- $1.03$2.85$1.30
21.15%
Downside
52 Weeks Volatility :64.04%
Upside
54.39%
Returns
| Period | Atai Life Sciences Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.11% | 7.0% | 0.0% |
6 Months | -22.62% | 7.0% | 0.0% |
1 Year | -10.34% | 17.2% | 0.0% |
3 Years | -91.67% | 18.0% | -20.0% |
Highlights
Market Capitalization | 206.4M |
Book Value | $1.0 |
Earnings Per Share (EPS) | -0.36 |
Wall Street Target Price | 11.6 |
Profit Margin | 0.0% |
Operating Margin TTM | -9424.54% |
Return On Assets TTM | -27.97% |
Return On Equity TTM | -31.51% |
Revenue TTM | 378.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 58.699999999999996% |
Gross Profit TTM | 233.0K |
EBITDA | -104.7M |
Diluted Eps TTM | -0.36 |
Quarterly Earnings Growth YOY | -0.97 |
EPS Estimate Current Year | -0.79 |
EPS Estimate Next Year | -0.68 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.16 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 792.31%
Technicals Summary
Sell
Neutral
Buy
Atai Life Sciences Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atai Life Sciences Nv | 11.11% | -22.62% | -10.34% | -91.67% | -93.32% |
 Regeneron Pharmaceuticals, Inc. | -0.3% | 20.26% | 38.56% | 78.77% | 303.42% |
 Novo Nordisk A/s | 1.92% | 1.8% | 42.06% | 173.92% | 453.76% |
 Alnylam Pharmaceuticals, Inc. | 0.91% | 78.6% | 37.4% | 41.12% | 212.93% |
 Vertex Pharmaceuticals Incorporated | 2.95% | 18.74% | 38.91% | 157.61% | 173.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atai Life Sciences Nv | NA | NA | NA | -0.79 | -0.32 | -0.28 | NA | 1.0 |
Regeneron Pharmaceuticals, Inc. | 30.86 | 30.86 | 1.59 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.01 | 46.01 | 2.08 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atai Life Sciences Nv | Buy | $206.4M | -93.32% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $128.4B | 303.42% | 30.86 | 32.04% |
Novo Nordisk A/s | Buy | $600.4B | 453.76% | 46.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 212.93% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.3B | 173.37% | 32.84 | -4.74% |
Insights on Atai Life Sciences Nv
Increasing Revenue
Revenue is up for the last 2 quarters, 18.0K → 273.0K (in $), with an average increase of 93.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, 44.24M → -57.31M (in $), with an average decrease of 100.6% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 52.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 173.9% return, outperforming this stock by 265.6%
Institutional Holdings
Morgan Stanley - Brokerage Accounts
1.59%BlackRock Inc
0.78%Brown University
0.43%Two Sigma Investments LLC
0.43%Millennium Management LLC
0.39%Vanguard Group Inc
0.25%
Company Information
who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Organization | Atai Life Sciences Nv |
Employees | 83 |
CEO | Mr. Christian Angermayer |
Industry | Commercial Services |
Discover More
A Spac I Acquisition Corp
$1.30
+5.69%
Keyarch Acquisition Corp
$1.30
+5.69%
Connexa Sports Technologies Inc
$1.30
+5.69%
Us Value Etf
$1.30
+5.69%
First Wave Biopharma Inc
$1.30
+5.69%
Global X Msci Next Emerging
$1.30
+5.69%
Fat Projects Acquisition Corp
$1.30
+5.69%
Capital Link Global Fintech
$1.30
+5.69%
Applied Uv Inc
$1.30
+5.69%